Singapore, June 28, 2010: Hosted by Global Leaders Institute, world vaccine industry leaders will convene at VacChina 2010 on Sept 15-16, 2010 in Shanghai, China. The two-day executive summit will explore the major partnering opportunities in the vaccine industry in China.
According to the organizers, the goal of the summit is to bridge the China vaccine industry with the world in terms of vaccine R&D and production innovation and address needs of the entire industry to improve vaccine quality and safety.
At the end of 2009, the Chinese vaccine industry raised so much concern worldwide that the headlines of the business media were occupied by various kinds of news about vaccine enterprises. For example, Sinovac Biotech successfully landed the Nasdaq, then Simcere, a pharmaceutical company-based in Jiangsu Province and listed on the NYSE, announced a 50.8 percent stake in Ealong Biotech and took control of the latter, and finally Novartis, acquired an 85 percent equity in Tianyuan Bio-Pharmaceutical, a vaccine producer, for RMB 850 million.
These deals indicate that the investors and foreign pharmaceutical giants have not slowed down their pace to enter China's vaccine market, even in the face of this economic recession.
Over 150 attendees from vaccine producers home and abroad will gather under the same roof to elaborate on themes on the evolution of China's vaccine market and make comparisons to other emerging markets.
Other topics will include the role of vaccines in the overall healthcare reform efforts in China and associated pricing strategies, future prospects of foreign vaccine products into China's EPI, China's intellectual property landscape, vaccine manufacturing in China, quality and safety from design to operations, bridging the gap between R&D and production, low cost novel purification platforms for vaccine production capacity and quality.
Renowned presenters speaking at the main conference on Sept 15 and 16 include Weidong Yin from Sinovac China, Xiaohang Ding from Zhejiang Tianyuan Bio-Pharmaceutical, Bing Zeng from Sinopharm, Xiaohan Du from Simcere Pharmaceutical, Pierre Trotemann from Sanofi Pasteur and Shou-Bai Chao from MedImmune.